Company registration number 07177056 (England and Wales)
BALTIC MEDICAL CENTRE LIMITED
FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
PAGES FOR FILING WITH REGISTRAR
BALTIC MEDICAL CENTRE LIMITED
CONTENTS
Page
Statement of financial position
1
Notes to the financial statements
2 - 7
BALTIC MEDICAL CENTRE LIMITED
STATEMENT OF FINANCIAL POSITION
AS AT
31 DECEMBER 2025
31 December 2025
- 1 -
2025
2024
Notes
£
£
£
£
Non-current assets
Property, plant and equipment
4
831,767
941,599
Current assets
Inventories
31,621
22,013
Trade and other receivables
5
145,744
141,058
Cash and cash equivalents
141,044
96,996
318,409
260,067
Current liabilities
6
(282,011)
(241,783)
Net current assets
36,398
18,284
Total assets less current liabilities
868,165
959,883
Non-current liabilities
7
(1,393,667)
(1,589,525)
Provisions for liabilities
(30,000)
(30,000)
Net liabilities
(555,502)
(659,642)
Equity
Called up share capital
8
100
100
Retained earnings
(555,602)
(659,742)
Total equity
(555,502)
(659,642)
The director of the company has elected not to include a copy of the income statement within the financial statements.true
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The financial statements were approved and signed by the director and authorised for issue on 23 October 2026
D. Bumelyte
Director
Company Registration No. 07177056
BALTIC MEDICAL CENTRE LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
- 2 -
1
Accounting policies
Company information
Baltic Medical Centre Limited is a private company limited by shares incorporated in England and Wales. The registered office is Unit 121, Meridian Place, London, E14 9FE.
1.1
Accounting convention
These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.
The financial statements are prepared in pound sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest pound sterling.
The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.
1.2
Going concern
The company has access to funding through a related party loan facility, which is not repayable within the foreseeable future. In addition, the company's parent undertaking has confirmed its continued financial support to enable the company to meet its liabilities as they fall due. Accordingly, the director has a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future and has therefore adopted the going concern basis in preparing these financial statements.
1.3
Revenue
Revenue represents amounts receivable from the provision of medical services supplied during the year which is stated net of discounts.
Revenue is recognised when the services are provided and the amount of revenue can be measured reliably and it is probable that the economic benefits will be received.
1.4
Property, plant and equipment
Property, plant and equipment are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.
Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:
Leasehold improvements
Straight line over the lease term
Plant and machinery
25% reducing balance
Fixtures, fittings & equipment
25% reducing balance
The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to the income statement.
1.5
Impairment of non-current assets
At each reporting period end date, the company reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).
BALTIC MEDICAL CENTRE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 3 -
Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.
If the recoverable amount of an asset is estimated to be less than its carrying amount, the carrying amount of the asset is reduced to its recoverable amount. An impairment loss is recognised immediately in the income statement.
1.6
Inventories
Inventories are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the inventories to their present location and condition.
Inventories are valued on a first in first out basis.
At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of inventories over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in the income statement.
1.7
Cash and cash equivalents
Cash and cash equivalents are basic financial assets and are represented by cash deposits held at the company's primary bank and cash in hand.
1.8
Financial instruments
The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ of FRS 102 to all of its financial instruments.
Financial instruments are recognised in the company's statement of financial position when the company becomes party to the contractual provisions of the instrument.
Basic financial assets
Basic financial assets, which include trade and other receivables and cash and bank balances, are initially measured at their transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method. Financial assets classified as receivable within one year are not amortised.
Impairment of financial assets
Financial assets, other than those held at fair value through profit and loss, are assessed for indicators of impairment at each reporting end date.
Financial assets are impaired where there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows have been affected. If an asset is impaired, the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset’s original effective interest rate. The impairment loss is recognised in profit or loss.
If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been, had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss.
BALTIC MEDICAL CENTRE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 4 -
Classification of financial liabilities
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.
Basic financial liabilities
Basic financial liabilities, including trade and other payables and loans from fellow group companies, are initially recognised at transaction price. Financial liabilities classified as payable within one year are not amortised.
Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.
Trade payables are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade payables are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.
1.9
Equity instruments
Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.
1.10
Provisions
Provisions are recognised when the company has a legal or constructive present obligation as a result of a past event, it is probable that the company will be required to settle that obligation and a reliable estimate can be made of the amount of the obligation.
The amount recognised as a provision is the best estimate of the consideration required to settle the present obligation at the reporting end date, taking into account the risks and uncertainties surrounding the obligation.
1.11
Employee benefits
The costs of short-term employee benefits are recognised as a liability and an expense. The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.
1.12
Retirement benefits
Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.
1.13
Leases
Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leases asset are consumed.
1.14
Foreign exchange
Transactions in currencies other than pound sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation are included in the income statement for the period.
BALTIC MEDICAL CENTRE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 5 -
2
Judgements and key sources of estimation uncertainty
In the application of the company’s accounting policies, the director is required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.
The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.
Key sources of estimation uncertainty
The estimates and assumptions which have a significant risk of causing a material adjustment to the carrying amount of assets and liabilities are as follows.
Dilapidation provision
Under the operating lease arrangements, the company is obliged to return its leasehold premises back to their original condition upon vacating the property. At the year end, the total provision for such costs was £30,000 (2024: £30,000).
3
Employees
The average monthly number of persons (including directors) employed by the company during the year was 22 (2024: 19).
4
Property, plant and equipment
Land and buildings
Plant and machinery etc
Total
£
£
£
Cost
At 1 January 2025 and 31 December 2025
1,264,730
355,893
1,620,623
Depreciation and impairment
At 1 January 2025
407,447
271,577
679,024
Depreciation charged in the year
88,753
21,079
109,832
At 31 December 2025
496,200
292,656
788,856
Carrying amount
At 31 December 2025
768,530
63,237
831,767
At 31 December 2024
857,283
84,316
941,599
BALTIC MEDICAL CENTRE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 6 -
5
Trade and other receivables
2025
2024
Amounts falling due within one year:
£
£
Trade receivables
7,319
8,359
Amounts owed by group undertakings
7,131
7,131
Other receivables
94,394
88,668
108,844
104,158
Amounts falling due after more than one year:
Rent deposits (repayable at the end of the lease term)
36,900
36,900
Total debtors
145,744
141,058
6
Current liabilities
2025
2024
£
£
Trade payables
170,855
133,172
Other taxation and social security
20,378
15,152
Other payables
90,778
93,459
282,011
241,783
7
Non-current liabilities
2025
2024
£
£
Other payables
1,393,667
1,589,525
During the year ended 31 December 2021, the company secured a loan facility from an entity under common control, in order to finance the development of leasehold premises to be used for the provision of medical services. The loan is unsecured and interest is payable at 3% per annum. The loan is repayable from January 2030 over a 12 month period.
As at 31 December 2025, the total loan facility provided to the company was £1.2 million (2024: £1.4 million). During the year, interest has been charged on the loan totalling £39,653 (2024: £42,000). All of the interest remains outstanding at the year end.
BALTIC MEDICAL CENTRE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 7 -
8
Called up share capital
2025
2024
£
£
Ordinary share capital
Issued and fully paid
100 Ordinary shares of £1 each
100
100
9
Audit report information
As the income statement has been omitted from the filing copy of the financial statements, the following information in relation to the audit report on the statutory financial statements is provided in accordance with s444(5B) of the Companies Act 2006:
The auditor's report was unqualified.
The senior statutory auditor was Mark Bailey FCA CTA.
The auditor was TC Group.
10
Operating lease commitments
Lessee
At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, as follows:
2025
2024
£
£
Within one year
188,184
193,445
Between two and five years
654,079
698,263
In over five years
488,811
632,416
1,331,074
1,524,124
11
Related party transactions
The company has taken advantage of the exemption under FRS 102 Section 33 from disclosing transactions with its parent and fellow group undertakings. The parent company is Northway Holdings Limited, which prepares consolidated financial statements that are publicly available at Unit 121 Meridian Place, London, United Kingdom, E14 9FE.
As at the year end, the company was owed £Nil (2024: £6,706) by a beneficiary of the ultimate controlling party.
12
Parent company
The company is a subsidiary of Northway Holdings Limited, a company incorporated in England & Wales (registration number: 04691066), with its registered office address at Unit 121 Meridian Place, London, E14 9FE.
The ultimate controlling party is The Bumelis Family Trust.
2025-12-312025-01-01falsefalsefalse23 October 2026CCH SoftwareCCH Accounts Production 2026.300No description of principal activityD. Bumelyte071770562025-01-012025-12-31071770562025-12-31071770562024-12-3107177056core:LandBuildings2025-12-3107177056core:OtherPropertyPlantEquipment2025-12-3107177056core:LandBuildings2024-12-3107177056core:OtherPropertyPlantEquipment2024-12-3107177056core:WithinOneYear2025-12-3107177056core:WithinOneYear2024-12-3107177056core:CurrentFinancialInstrumentscore:WithinOneYear2025-12-3107177056core:CurrentFinancialInstrumentscore:WithinOneYear2024-12-3107177056core:CurrentFinancialInstruments2025-12-3107177056core:CurrentFinancialInstruments2024-12-3107177056core:Non-currentFinancialInstruments2025-12-3107177056core:Non-currentFinancialInstruments2024-12-3107177056core:ShareCapital2025-12-3107177056core:ShareCapital2024-12-3107177056core:RetainedEarningsAccumulatedLosses2025-12-3107177056core:RetainedEarningsAccumulatedLosses2024-12-3107177056core:ShareCapitalOrdinaryShareClass12025-12-3107177056core:ShareCapitalOrdinaryShareClass12024-12-3107177056core:HedgingReserve2023-12-3107177056bus:Director12025-01-012025-12-3107177056core:LeaseholdImprovementscore:LeasedAssetsHeldAsLessee2025-01-012025-12-3107177056core:PlantMachinery2025-01-012025-12-3107177056core:FurnitureFittings2025-01-012025-12-31071770562024-01-012024-12-3107177056core:LandBuildings2024-12-3107177056core:OtherPropertyPlantEquipment2024-12-31071770562024-12-3107177056core:LandBuildings2025-01-012025-12-3107177056core:OtherPropertyPlantEquipment2025-01-012025-12-3107177056core:Non-currentFinancialInstrumentscore:AfterOneYear2025-12-3107177056core:Non-currentFinancialInstrumentscore:AfterOneYear2024-12-3107177056bus:OrdinaryShareClass12025-01-012025-12-3107177056bus:OrdinaryShareClass12025-12-3107177056core:BetweenTwoFiveYears2025-12-3107177056core:BetweenTwoFiveYears2024-12-3107177056core:MoreThanFiveYears2025-12-3107177056core:MoreThanFiveYears2024-12-3107177056bus:PrivateLimitedCompanyLtd2025-01-012025-12-3107177056bus:SmallCompaniesRegimeForAccounts2025-01-012025-12-3107177056bus:FRS1022025-01-012025-12-3107177056bus:Audited2025-01-012025-12-3107177056bus:FullAccounts2025-01-012025-12-31xbrli:purexbrli:sharesiso4217:GBP